ChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In Sight

ChronoScale Holdings (CHRN) shares rose after expanding AI infrastructure contracts, projecting a $1 billion annualized revenue run rate by Q3 2027. The company also completed the sale of its Ekso Bionics business. CHRN is trading at $20.33, above its 20-day and 100-day SMAs but below the 50-day SMA. Analysts rate CHRN as Strong Buy with an average price target of $32.

Original reporting
Published Oct 2, 2026, 4:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 5:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In Sight — source image
Decision brief

The 30-second read

$CHRNBullishMed
01

Why it matters

The announcement of new contracts and a strategic divestiture provides fresh growth catalysts, likely prompting short‑term buying pressure.

02

Market read

First‑report of sizable AI contracts and a strategic asset sale, offering a new catalyst for CHRN.

03

What to watch

Potential competition from larger cloud players and the need for sustained capital to fund infrastructure expansion.

Relevance 7/10Novelty 7/10Timing: today, after‑hours reaction

Background

ChronoScale (NASDAQ:CHRN) is a small‑cap AI‑infrastructure provider that recently refocused on GPU‑based services after selling its Ekso Bionics unit.

Company-level read

Ticker impact

$CHRNBullishHigh confidence
Context

ChronoScale announced expanded AI infrastructure contracts targeting a $1 billion annualized revenue run rate and completed the sale of its Ekso Bionics business.

Expected impact

likely upside as the market prices in the projected revenue run‑rate

Evidence & confidence

Fresh primary disclosure of sizable contracts and a strategic divestiture, both not previously reported.

Market effects

Strengthens the AI‑infrastructure niche and may boost related GPU and cloud providers.

Primarily U.S. tech market, limited broader regional effect.

Adds to the narrative of growing AI spend worldwide.

Counterpoint

The $1 billion run‑rate is contingent on execution; delays or capital constraints could dampen upside.

Key entities

  • ChronoScale Holdings Corp.

    AI infrastructure provider expanding its contract pipeline.

  • Wandercraft

    Acquirer of ChronoScale's Ekso Bionics business.

Related articles

$SLNHMed

Soluna and Applied Digital to build 50 MW wind-powered AI data center in Texas

Soluna (SLNH) and Applied Digital (APLD) agreed to form a joint venture to build a 50 MW wind-powered AI data center in Texas. Applied will own 51%, providing capital, while Soluna contributes land and power assets. ChronoScale (CHRN), majority-owned by Applied, may lease the facility. The project is expected to close by year-end, with Phase 1 powered by Soluna's Briscoe Wind Farm and the grid.

$CHRNMedAI 8/10

ChronoScale Reports Fiscal First Quarter 2027 Results

ChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ChronoScale Reports Fiscal First Quarter 2027 Results MENLO PARK, Calif. – October 15, 2026 — ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence

$CHRNHighAI 8/10

ChronoScale stock jumps on $1B revenue target from AI deals

ChronoScale Corp (CHRN) shares rose 3% after-hours after announcing deals expected to reach $1B annualized revenue run rate by Q3 2027. The AI infrastructure provider signed a contract extension and new customer agreement, though revenue is subject to deployment and capital risks. The company also sold its Ekso Bionics unit to focus on core AI infrastructure business.